M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Phase 1

Recruiting

Conditions: Pancreas Cancer

Interventions: Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: IM156

First Posted Date: 2022-08-11

Last Posted Date: 2024-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT05497778

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

Active, not recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Behavioral: Survey Administration

First Posted Date: 2022-08-11

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT05496972

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Early Phase 1

Recruiting

Conditions: Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib
Other: Brexucabtagene Autoleucel
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2022-08-10

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05495464

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Behavioral: Navigator Phone Calls
Behavioral: Exit Interview

First Posted Date: 2022-08-04

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05488444

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Phase 2

Recruiting

Conditions: Sleep
Anxiety
Depression
Fatigue
Cancer

Interventions: Other: Placebo for Melatonin
Drug: Melatonin
Drug: Methylphenidate

First Posted Date: 2022-07-26

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 188

Registration Number: NCT05474846

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Use of Water Warming/Cooling Garment to Maintain a Constant Intraoperative Core Target Temperature in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Proof-of-Concept Study

Early Phase 1

Withdrawn

Conditions: Hyperthermic Intraperitoneal

Interventions: Device: Allon System

First Posted Date: 2022-07-26

Last Posted Date: 2023-05-06

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05474352

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Phase 2

Recruiting

Conditions: Cervical Cancer
Metastatic Cancer

Interventions: Drug: Lorigerlimab

First Posted Date: 2022-07-26

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05475171

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Phase 1

Active, not recruiting

Conditions: Tumor
Melanoma
Metastatic Melanoma

Interventions: Drug: OBX-115
Drug: Acetazolamide
Drug: Cyclophosphamide
Drug: Furosemide
Drug: Mesna
Drug: Fludarabine Phosphate

First Posted Date: 2022-07-22

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT05470283

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)

Phase 2

Active, not recruiting

Conditions: Cancer
Pediatric ALL

Interventions: Other: IPAD
Other: Augmented Reality

First Posted Date: 2022-07-20

Last Posted Date: 2024-10-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT05466994

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Phase 2

Terminated

Conditions: Leukemia, Lymphoblastic
Leukemia

Interventions: Drug: CB-103
Drug: Venetoclax

First Posted Date: 2022-07-19

Last Posted Date: 2024-08-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT05464836

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy